ProCE Banner Activity

COMMANDS: Luspatercept vs Epoetin alfa for ESA-Naive Transfusion-Dependent Lower-Risk MDS

Conference Coverage
Slideset

In ESA-naive patients with transfusion-dependent lower-risk MDS, luspatercept was associated with a higher rate of transfusion independence and increased hemoglobin than epoetin alfa treatment.

Released: June 05, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AbbVie, Geron, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AbbVie

Geron

Jazz Pharmaceuticals

Lilly

Merck Sharp & Dohme Corp.

Novartis